Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Anti CTLA-4 antibodies (1)
- Anti PD-1 antibodies (1)
- Anti PD-L1 therapy (1)
- Arrhythmia (1)
- Atrial Fibrillation (1)
-
- Atrial Flutter (1)
- Bruton tyrosine kinase inhibitor (1)
- Cardiotoxic adverse effect (1)
- Cardiotoxicities (1)
- Cardiotoxicity (1)
- Empyema (1)
- Female (1)
- Fistula (1)
- Humans (1)
- Ibrutinib (1)
- Immune checkpoint inhibitor (ICI) (1)
- Immunotherapy (1)
- Lung Resection (1)
- Lymphoma (1)
- Lymphoproliferative Disorders (1)
- Male (1)
- Middle Aged (1)
- Prospective Studies (1)
- Tachycardia, Supraventricular (1)
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments Of Lymphoproliferative Disorders, Saadia Sherazi, Susan Schleede, Scott Mcnitt, Carla Casulo, Jeremiah E. Moore, Eugene Storozynsky, Arpan Patel, Neelima Vidula, Mehmet K. Aktas, Clive S. Zent, Ilan Goldenberg
Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments Of Lymphoproliferative Disorders, Saadia Sherazi, Susan Schleede, Scott Mcnitt, Carla Casulo, Jeremiah E. Moore, Eugene Storozynsky, Arpan Patel, Neelima Vidula, Mehmet K. Aktas, Clive S. Zent, Ilan Goldenberg
Division of Cardiology Faculty Papers
Background
There are limited data on risk of arrhythmias among patients with lymphoproliferative disorders. We designed this study to determine the risk of atrial and ventricular arrhythmia during treatment of lymphoma in a real‐world setting.Methods and Results
The study population comprised 2064 patients included in the University of Rochester Medical Center Lymphoma Database from January 2013 to August 2019. Cardiac arrhythmias—atrial fibrillation/flutter, supraventricular tachycardia, ventricular arrhythmia, and bradyarrhythmia—were identified using International Classification of Diseases, Tenth Revision (ICD‐10) codes. Multivariate Cox regression analysis was used to assess the risk of arrhythmic events with treatments categorized as Bruton tyrosine …Overcoming The Cardiac Toxicities Of Cancer Therapy Immune Checkpoint Inhibitors, Omoruyi Credit Irabor, Nicolas Nelson, Yash Shah, Muneeb Khan Niazi, Spencer Poiset, Eugene Storozynsky, Dinender K Singla, D. Craig Hooper, Bo Lu
Overcoming The Cardiac Toxicities Of Cancer Therapy Immune Checkpoint Inhibitors, Omoruyi Credit Irabor, Nicolas Nelson, Yash Shah, Muneeb Khan Niazi, Spencer Poiset, Eugene Storozynsky, Dinender K Singla, D. Craig Hooper, Bo Lu
Division of Cardiology Faculty Papers
Immune checkpoint inhibitors (ICIs) have led recent advances in the field of cancer immunotherapy improving overall survival in multiple malignancies with abysmal prognoses prior to their introduction. The remarkable efficacy of ICIs is however limited by their potential for systemic and organ specific immune-related adverse events (irAEs), most of which present with mild to moderate symptoms that can resolve spontaneously, with discontinuation of therapy or glucocorticoid therapy. Cardiac irAEs however are potentially fatal. The understanding of autoimmune cardiotoxicity remains limited due to its rareness. In this paper, we provide an updated review of the literature on the pathologic mechanisms, diagnosis, …
Conservatively Managed Chronic Bronchopleural Fistula After Lung Cancer Tri-Modality Therapy: A Case Report, Nilanjan Haldar, Christian Fernandez, Nathaniel R. Evans Iii, Maria Werner-Wasik
Conservatively Managed Chronic Bronchopleural Fistula After Lung Cancer Tri-Modality Therapy: A Case Report, Nilanjan Haldar, Christian Fernandez, Nathaniel R. Evans Iii, Maria Werner-Wasik
Division of Cardiology Faculty Papers
No abstract provided.